Mutant p53 and mTOR/PKM2 regulation in cancer cells

IUBMB Life

Volumn , Issue , 2016, Pages 722-726

  Dando, Ilaria ^a   Cordani, Marco ^a   Donadelli, Massimo ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

cancer; chemoresistance; mTOR; mutant p53; PKM2

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P53; PYRUVATE KINASE; PYRUVATE KINASE ISOFORM M2; UNCLASSIFIED DRUG;

AEROBIC GLYCOLYSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; DRUG POTENCY; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 84983238510     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1534     Document Type: Article

References (28)

1. Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., et al. (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501.
2. Lang, G. A., Iwakuma, T., Suh, Y. A., Liu, G., Rao, V. A., et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861–872.
3. Aschauer, L. and Muller, P. A. (2016) Novel targets and interaction partners of mutant p53 Gain-Of-Function. Biochem. Soc. Trans. 44, 460–466.
4. Haupt, S., Raghu, D., and Haupt, Y. (2016) Mutant p53 drives cancer by subverting multiple tumor suppression pathways. Front. Oncol. 6, 12.
5. Zoncu, R., Efeyan, A., and Sabatini, D. M. (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21–35.
6. Li, Z., Yang, P., and Li, Z. (2014) The multifaceted regulation and functions of PKM2 in tumor progression. Biochim. Biophys. Acta 1846, 285–296.
7. Goldberg, M. S. and Sharp, P. A. (2012) Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J. Exp. Med. 209, 217–224.
8. Brummelkamp, T. R., Bernards, R., and Agami, R. (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550–553.
9. Cordani, M., Oppici, E., Dando, I., Butturini, E., Dalla Pozza, E., et al. (2016) Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition. Mol. Oncol. doi: 10.1016/j.molonc.2016.04.001.
10. Zhou, G., Wang, J., Zhao, M., Xie, T. X., Tanaka, N., et al. (2014) Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol. Cell 54, 960–974.
11. Yallowitz, A. R., Li, D., Lobko, A., Mott, D., Nemajerova, A., et al. (2015) Mutant p53 amplifies epidermal growth factor receptor family signaling to promote mammary tumorigenesis. Mol. Cancer Res. 13, 743–754.
12. Muller, P. A., Trinidad, A. G., Timpson, P., Morton, J. P., Zanivan, S. et al. (2013) Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 32, 1252–1265.
13. Zhao, J., Zhao, D., Poage, G. M., Mazumdar, A., Zhang, Y., et al. (2015) Death-associated protein kinase 1 promotes growth of p53-mutant cancers. J. Clin. Invest. 125, 2707–2720.
14. Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., et al. (2011) Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145, 732–744.
15. Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., et al. (2011) Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 480, 118–122.
16. Yang, W. and Lu, Z. (2013) Nuclear PKM2 regulates the Warburg effect. Cell Cycle 12, 3154–3158.
17. Wu, H., Li, Z., Yang, P., Zhang, L., Fan, Y., et al. (2014) PKM2 depletion induces the compensation of glutaminolysis through beta-catenin/c-Myc pathway in tumor cells. Cell. Signal. 23, 97–2405.
18. Gao, X., Wang, H., Yang, J. J., Liu, X., and Liu, Z. R. (2012) Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 45, 598–609.
19. Yang, P., Li, Z., Fu, R., Wu, H., and Li, Z. (2014) Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling. Cell. Signal. 26, 1853–1862.
20. Wu, M., An, J., Zheng, Q., Xin, X., Lin, Z., et al. (2016) Double mutant P53 (N340Q/L344R) promotes hepatocarcinogenesis through upregulation of Pim1 mediated by PKM2 and LncRNA CUDR. Oncotarget. doi: 10.18632/oncotarget.9089.
21. Iqbal, M. A., Gupta, V., Gopinath, P., Mazurek, S., and Bamezai, R. N. (2014) Pyruvate kinase M2 and cancer: an updated assessment. FEBS Lett. 588, 2685–2692.
22. Masciarelli, S., Fontemaggi, G., Di Agostino, S., Donzelli, S., Carcarino, E., et al. (2014) Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene 33, 1601–1608.
23. Fiorini, C., Cordani, M., Padroni, C., Blandino, G., Di Agostino, S., et al. (2015) Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochim. Biophys. Acta 1853, 89–100.
24. Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz, R., et al. (2015) Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature 523, 352–356.
25. Li, J., Zhu, J., Cao, B., and Mao, X. (2014) The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma. Curr. Pharm. Design 20, 125–135.
26. Sun, Q., Chen, X., Ma, J., Peng, H., Wang, F., et al. (2011) Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 108, 4129–4134.
27. He, Y., Wang, Y., Liu, H., Xu, X., He, S., et al. (2015) Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance. Leuk. Res. 39, 1428–1436.
28. Kim, D. J., Park, Y. S., Kang, M. G., You, Y. M., Jung, Y., et al. (2015) Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells. Exp. Cell Res. 336, 119–129.